Home Sectors Healthcare Current Valuation: MiMedx Group Inc (NASDAQ: MDXG)

Current Valuation: MiMedx Group Inc (NASDAQ: MDXG)

11
0
SHARE

MiMedx Group Inc is in the medical devices industry and is part of the healthcare sector. The company CEO is David Coles. MiMedx Group Inc is a developer, manufacturer and marketer of patent-protected regenerative biomaterial products and bioimplants processed from human amniotic membrane.

Previous Intraday Trading Performance:

The MDXG stock showed a previous change of 0.69% with an open at 4.34 and a close of 4.35. It reached an intraday high of 4.49 and a low of 4.26.

PR Newswire:  MiMedx Receives Regulatory Approval to Commercialize Product Portfolio in Australia

Liquidity:

The stock has a market cap of $483.0m with 111.0m shares outstanding, of which the float is 97.5m shares. Trading volume reached 1,457,064 shares compared to its average volume of 4,029,008 shares. Based on the current average volume and close price, the trading liquidity is bad, highly speculative and an investor may want to avoid this stock.

Historical Trading Performance:

Over the last five trading days, MiMedx Group Inc shares returned 4.57% and in the past 30 trading days it returned -31.82%. Over three months, it changed -46.03%. In one year it has changed -71.44% and within that year its 52-week high was 18.25 and its 52-week low was 3.01. MDXG stock is 44.76% above its 52 Week Low.

Our calculations show a 200 day moving average of 9.24 and a 50 day moving average of 5.08. Currently MDXG stock is trading -52.93% below its 200 day moving average and may not be a good opportunity to buy as it may continue to trend down.

PR Newswire:  MiMedx Receives Regulatory Approval to Commercialize Product Portfolio in Australia

Earnings:

The last annual fiscal EPS for the company was reported at 0.11 that ended on 31st of December 2016, which according to the previous close, that is a PE of 39.55. The TTM EPS is 0.12, which comes to a TTM PE of 36.25.

The following are the last four quarter reported earnings per share:
03-31-2018:  0.00 (estimated)
12-31-2017:  0.00
09-30-2017:  0.05
06-30-2017:  0.07

Base on our calculations, the intrinsic value per share is 8.30, which means it is possibly undervalued and has a margin of safety of 47.59%

Indicators to Watch:

Based on the latest filings, there is 12.20% of insider ownership and 73.70% of institutional ownership. Short-interest is 50,128,118, which is 45.15% of shares outstanding. The short-interest ratio or days-to-cover ratio is 12.62. This stock has a high level of short interest and may fall in value in the near term.

The current calculated beta is 1.52

SeekingAlpha:  Methode Electronics beats by $0.25, beats on revenue

Fundamental Indicators:

Based on last reported financials, the company's return on equity is 26.59%, return on assets is 19.61%, profit margin is 20.64%, price-to-sales is 5.67 and price-to-book is 3.37.

Company Scores:

All scores are out of six:
 5  :Valuation Score
 6  :Past Performance Score
 6  :Financial Strength Score
 3  :Future Growth Score
 0  :Dividend Score
 5  :Overall Score

SHARE
John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks. Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.

LEAVE A REPLY

Please enter your comment!
Please enter your name here